Open AccessNovel insights into the systemic treatment of lung cancer malignant pleural effusion
Author(s) -
Tissot Claire,
Gay Pierre,
Brun Clément,
Froudarakis Marios E.
Publication year - 2019
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.13005
Subject(s) - medicine , lung cancer , malignant pleural effusion , malignancy , pleural effusion , disease , oncology , cancer , stage (stratigraphy) , lung , treatment of lung cancer , paleontology , biology
Lung cancer is the most common fatal malignancy worldwide. Approximately 75% of non‐small‐cell lung cancer (NSCLC) patients are diagnosed at an advanced or a metastatic stage. Since 2007, NSCLC patients with malignant pleural effusion (MPE) are staged as M1 disease. During the last decades, chemotherapeutic agents failed to offer a significant improvement of survival in patients with metastatic disease. The current review aims to summarize the actual situation of the recently developed therapies in patients with lung cancer and MPE.